Meeting
2021 ASCO Annual Meeting
CaboRISE: A phase II study evaluating reduced starting dose and dose escalation of cabozantinib as second-line therapy for advanced HCC in patients with compensated liver cirrhosis.
Authors
Jorg Trojan
University Hospital, Johann Wolfgang Goethe-University Frankfurt, Frankfurt, Germany
Jorg Trojan , Stefan Pluntke , Florian van Boemmel , Ursula Ehmer , Thorsten Oliver Goetze , Lutz Jacobasch , Daniel Pink , Christina Kopp , Sarah Lehnerts , Johanna Riedel , Oliver Waidmann , Fabian Finkelmeier , Michael Geißler
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer
Clinical Trial Registration Number
NCT04522908
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr TPS4163)
DOI
10.1200/JCO.2021.39.15_suppl.TPS4163
Abstract #
TPS4163
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Treatment of hepatocellular carcinoma with tyrosine kinase inhibitors: Real-world outcomes from the West of Scotland.
First Author: Gregory Naylor
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Cost-utility analysis of sequential therapy with sorafenib followed by regorafenib versus single-line therapies in advanced hepatocellular carcinoma.
First Author: Jamie Grossman
Poster
2023 ASCO Annual Meeting
Geographical and baseline clinical characteristics of participants enrolled in hepatocellular carcinoma (HCC) trials: Analysis of US FDA approvals.
First Author: M. Naomi Horiba
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Real world data of systemic therapy for hepatocellular carcinoma in Japan: HERITAGE study.
First Author: Yoshinari Asaoka